Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of VGA039 Following Intravenous or Subcutaneous Administration of Single Ascending Doses in Healthy Adults and
Adult Patients with von Willebrand Disease
Not Available
I
Wheeler, Allison
NCT05776069
NCBH2304-VEGA
REDUCE Post Approval Study - GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO)
Not Available
Piana, Robert
NCT03821129
CRE-ARR0003
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Patients with Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
N/A
Oluwole, Olalekan
NCT05346835
VICC-XDCTT24033
Open-Label Safety Study in Adults and Adolescents with Haemophilia A with and without FVIII Inhibitors Switching Directly from Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis
Not Available
III
Walker, Shannon
NCT05878938
NCBH2302-FRONTIER5
MRI and 18F-Fluoromisonidazole PET/CT Scan for Assessing Tumor Hypoxia and Guiding Adaptive Radiation Therapy in Patients With Head and Neck Cancer or Brain Metastases
Miscellaneous
Miscellaneous
This clinical trial is studying how well magnetic resonance imaging (MRI) in combination with 18F-fluoromisonidazole (18F-FMISO) positron emission tomography (PET)/computed tomography (CT) scans works in assessing a decrease in the amount of oxygen (hypoxia) in tumor cells and in guiding adaptive radiation treatment in patients with head and neck cancer or cancer that has spread to the brain from where it first started (brain metastasis). Both head and neck cancer and brain metastases can be treated with radiation. Previous research studies have shown that the amount of oxygen that goes towards cancer cells prior to their radiation treatments predicts how the cancer cells will respond to radiation treatment. MRI is a type of imaging technique that uses radio waves and large magnets to produce detailed images of areas inside the body. 18F-FMISO is a radioactive substance that binds to hypoxic tumor cells and emits radiation, allowing the tumor cells to be visualized using PET/CT, which is an imaging technique that combines PET and CT in a single machine. It is used to make detailed, computerized images of inside the body. By combining MRI with 18F-FMISO PET/CT, researchers may be able to develop an MRI sequence that can be used to evaluate hypoxia in tumor cells and predict response to treatment in patients with head and neck cancer or brain metastases.
Miscellaneous
Early I
De vis, Jill
NCT05996432
VICC-EDMDT23195
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients
Supportive Care
Supportive Care
This study will assess pharmacokinetic (PK)/pharmacodynamic (PD) relationships and whether
BXQ-350 may decrease the intensity and/or duration of chemotherapy induced peripheral
neuropathy (CIPN) thereby improving quality of life (QoL) in cancer patients who have been
exposed to oxaliplatin and/or taxane-based chemotherapy. This study includes two randomized,
placebo controlled, blinded treatment cycles of BXQ-350/placebo, an optional open-label
BXQ-350 treatment period, and an unblinded Post-Treatment Follow-up period.
BXQ-350 may decrease the intensity and/or duration of chemotherapy induced peripheral
neuropathy (CIPN) thereby improving quality of life (QoL) in cancer patients who have been
exposed to oxaliplatin and/or taxane-based chemotherapy. This study includes two randomized,
placebo controlled, blinded treatment cycles of BXQ-350/placebo, an optional open-label
BXQ-350 treatment period, and an unblinded Post-Treatment Follow-up period.
Supportive Care
Early I
Agarwal, Rajiv
NCT05291286
VICC-DTSUP23096
A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors
Multiple Cancer Types
This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Neuro-Oncology,
Pediatrics
III
Esbenshade, Adam
NCT04939597
COGACCL2031
Studying the Effect of Levocarnitine in Protecting the Liver from Chemotherapy for Leukemia or Lymphoma
Multiple Cancer Types
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy vs. standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Leukemia,
Pediatric Leukemia
III
Borinstein, Scott
NCT05602194
VICC-NTPED23475
Identifying Best Approach in Improving Quality of Life and Survival after a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients with Blood Diseases
Hematologic
Hematologic
This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and palliative care (SPC), focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects. While a second approach, clinical management of comorbidities (CMC) focuses on managing multiple diseases, other than cancer, such as heart or lung diseases through physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education. Giving SPC, CMC, or a combination of both may work better in improving quality of life and survival after a donor stem cell transplant compared to standard of care in patients with blood diseases.
Hematologic
II/III
Jayani, Reena
NCT03870750
VICC-IDCTT23500